177 related articles for article (PubMed ID: 24451168)
1. Vaccines against human HER2 prevent mammary carcinoma in mice transgenic for human HER2.
De Giovanni C; Nicoletti G; Quaglino E; Landuzzi L; Palladini A; Ianzano ML; Dall'Ora M; Grosso V; Ranieri D; Laranga R; Croci S; Amici A; Penichet ML; Iezzi M; Cavallo F; Nanni P; Lollini PL
Breast Cancer Res; 2014 Jan; 16(1):R10. PubMed ID: 24451168
[TBL] [Abstract][Full Text] [Related]
2. Vaccination with human anti-trastuzumab anti-idiotype scFv reverses HER2 immunological tolerance and induces tumor immunity in MMTV.f.huHER2(Fo5) mice.
Ladjemi MZ; Chardes T; Corgnac S; Garambois V; Morisseau S; Robert B; Bascoul-Mollevi C; Ait Arsa I; Jacot W; Pouget JP; Pelegrin A; Navarro-Teulon I
Breast Cancer Res; 2011 Feb; 13(1):R17. PubMed ID: 21294885
[TBL] [Abstract][Full Text] [Related]
3. Interleukin-15 is required for immunosurveillance and immunoprevention of HER2/neu-driven mammary carcinogenesis.
Croci S; Nanni P; Palladini A; Nicoletti G; Grosso V; Benegiamo G; Landuzzi L; Lamolinara A; Ianzano ML; Ranieri D; Dall'Ora M; Iezzi M; De Giovanni C; Lollini PL
Breast Cancer Res; 2015 May; 17(1):70. PubMed ID: 25997501
[TBL] [Abstract][Full Text] [Related]
4. Targeting of the non-mutated tumor antigen HER2/neu to mature dendritic cells induces an integrated immune response that protects against breast cancer in mice.
Wang B; Zaidi N; He LZ; Zhang L; Kuroiwa JM; Keler T; Steinman RM
Breast Cancer Res; 2012 Mar; 14(2):R39. PubMed ID: 22397502
[TBL] [Abstract][Full Text] [Related]
5. HER2-targeted therapy reduces incidence and progression of midlife mammary tumors in female murine mammary tumor virus huHER2-transgenic mice.
Finkle D; Quan ZR; Asghari V; Kloss J; Ghaboosi N; Mai E; Wong WL; Hollingshead P; Schwall R; Koeppen H; Erickson S
Clin Cancer Res; 2004 Apr; 10(7):2499-511. PubMed ID: 15073130
[TBL] [Abstract][Full Text] [Related]
6. Immunoprevention of HER-2/neu transgenic mammary carcinoma through an interleukin 12-engineered allogeneic cell vaccine.
De Giovanni C; Nicoletti G; Landuzzi L; Astolfi A; Croci S; Comes A; Ferrini S; Meazza R; Iezzi M; Di Carlo E; Musiani P; Cavallo F; Nanni P; Lollini PL
Cancer Res; 2004 Jun; 64(11):4001-9. PubMed ID: 15173014
[TBL] [Abstract][Full Text] [Related]
7. Prime-boost vaccination with plasmid and adenovirus gene vaccines control HER2/neu+ metastatic breast cancer in mice.
Wang X; Wang JP; Rao XM; Price JE; Zhou HS; Lachman LB
Breast Cancer Res; 2005; 7(5):R580-8. PubMed ID: 16168101
[TBL] [Abstract][Full Text] [Related]
8. Her-2 DNA versus cell vaccine: immunogenicity and anti-tumor activity.
Whittington PJ; Radkevich-Brown O; Jacob JB; Jones RF; Weise AM; Wei WZ
Cancer Immunol Immunother; 2009 May; 58(5):759-67. PubMed ID: 18836716
[TBL] [Abstract][Full Text] [Related]
9. HSP110-HER2/neu chaperone complex vaccine induces protective immunity against spontaneous mammary tumors in HER-2/neu transgenic mice.
Manjili MH; Wang XY; Chen X; Martin T; Repasky EA; Henderson R; Subjeck JR
J Immunol; 2003 Oct; 171(8):4054-61. PubMed ID: 14530326
[TBL] [Abstract][Full Text] [Related]
10. Xenogeneic immunization in mice using HER2 DNA delivered by an adenoviral vector.
Gallo P; Dharmapuri S; Nuzzo M; Maldini D; Iezzi M; Cavallo F; Musiani P; Forni G; Monaci P
Int J Cancer; 2005 Jan; 113(1):67-77. PubMed ID: 15386429
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of mammary carcinoma development in HER-2/neu transgenic mice through induction of autoimmunity by xenogeneic DNA vaccination.
Pupa SM; Iezzi M; Di Carlo E; Invernizzi A; Cavallo F; Meazza R; Comes A; Ferrini S; Musiani P; Ménard S
Cancer Res; 2005 Feb; 65(3):1071-8. PubMed ID: 15705909
[TBL] [Abstract][Full Text] [Related]
12. A multi-DNA preventive vaccine for p53/Neu-driven cancer syndrome.
De Giovanni C; Nicoletti G; Palladini A; Croci S; Landuzzi L; Antognoli A; Murgo A; Astolfi A; Ferrini S; Fabbi M; Orengo AM; Amici A; Penichet ML; Aurisicchio L; Iezzi M; Musiani P; Nanni P; Lollini PL
Hum Gene Ther; 2009 May; 20(5):453-64. PubMed ID: 19215191
[TBL] [Abstract][Full Text] [Related]
13. An HER2 DNA vaccine with evolution-selected amino acid substitutions reveals a fundamental principle for cancer vaccine formulation in HER2 transgenic mice.
Jones RF; Reyes JD; Gibson HM; Jacob JB; Vaishampayan U; Ratner S; Chen K; Wei WZ
Cancer Immunol Immunother; 2019 Jul; 68(7):1143-1155. PubMed ID: 31177328
[TBL] [Abstract][Full Text] [Related]
14. Antibody-dependent natural killer cell-mediated cytotoxicity engendered by a kinase-inactive human HER2 adenovirus-based vaccination mediates resistance to breast tumors.
Triulzi C; Vertuani S; Curcio C; Antognoli A; Seibt J; Akusjärvi G; Wei WZ; Cavallo F; Kiessling R
Cancer Res; 2010 Oct; 70(19):7431-41. PubMed ID: 20823150
[TBL] [Abstract][Full Text] [Related]
15. Activity of DNA vaccines encoding self or heterologous Her-2/neu in Her-2 or neu transgenic mice.
Jacob J; Radkevich O; Forni G; Zielinski J; Shim D; Jones RF; Wei WZ
Cell Immunol; 2006 Apr; 240(2):96-106. PubMed ID: 16930573
[TBL] [Abstract][Full Text] [Related]
16. Chimeric rat/human HER2 efficiently circumvents HER2 tolerance in cancer patients.
Occhipinti S; Sponton L; Rolla S; Caorsi C; Novarino A; Donadio M; Bustreo S; Satolli MA; Pecchioni C; Marchini C; Amici A; Cavallo F; Cappello P; Pierobon D; Novelli F; Giovarelli M
Clin Cancer Res; 2014 Jun; 20(11):2910-21. PubMed ID: 24668647
[TBL] [Abstract][Full Text] [Related]
17. Heterologous human/rat HER2-specific exosome-targeted T cell vaccine stimulates potent humoral and CTL responses leading to enhanced circumvention of HER2 tolerance in double transgenic HLA-A2/HER2 mice.
Xie Y; Wu J; Xu A; Ahmeqd S; Sami A; Chibbar R; Freywald A; Zheng C; Xiang J
Vaccine; 2018 Mar; 36(11):1414-1422. PubMed ID: 29415817
[TBL] [Abstract][Full Text] [Related]
18. Induction of HER2 Immunity in Outbred Domestic Cats by DNA Electrovaccination.
Gibson HM; Veenstra JJ; Jones R; Vaishampayan U; Sauerbrey M; Bepler G; Lum L; Reyes J; Weise A; Wei WZ
Cancer Immunol Res; 2015 Jul; 3(7):777-86. PubMed ID: 25711535
[TBL] [Abstract][Full Text] [Related]
19. Delayed tumor onset and reduced tumor growth progression after immunization with a Her-2/neu multi-peptide vaccine and IL-12 in c-neu transgenic mice.
Wagner S; Jasinska J; Breiteneder H; Kundi M; Pehamberger H; Scheiner O; Zielinski CC; Wiedermann U
Breast Cancer Res Treat; 2007 Nov; 106(1):29-38. PubMed ID: 17203384
[TBL] [Abstract][Full Text] [Related]
20. Enhanced immunity by NeuEDhsp70 DNA vaccine Is needed to combat an aggressive spontaneous metastatic breast cancer.
Kim JH; Majumder N; Lin H; Chen J; Falo LD; You Z
Mol Ther; 2005 Jun; 11(6):941-9. PubMed ID: 15922965
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
